A year after failing to meet a trial endpoint, Travere Therapeutics can now relax. On 05 September 2024, the FDA upgraded FILSPARI’s conditional approval for the kidney disease IgA nephropathy to full approval.
FILSPARI’s complete approval broadens its use, permitting the small molecule blocker to help slow kidney function decline in adults at risk of disease progression. This also eliminates the prior necessity of having a specific urinary protein level.
FILSPARI is a first-in-class, orally active single-molecule that acts as a high-affinity dual-acting antagonist of the ETA and AT1 receptors, which are linked to the development of kidney disease. It is the fir...
